Cancers & treatments·Regimen libraryAdjuvant

Capecitabine (post-neoadjuvant)

Checked 2026-09-09

Residual invasive disease after neoadjuvant chemotherapy, HER2-negative

One cycle

every 21 days × 6-8 · about 18 weeks in total

21-day cycle × 6-8 (about 18 weeks)Oral Daily oral course

Components

Drug	Dose	Route	Days	Note
Capecitabine	1,250 mg/m² twice daily	Oral	D1-14

Cycles

6-8

21-day cycle

Emetogenicity

Low (10-30%)

G-CSF

Not routine

Notes

Benefit concentrated in triple-negative disease; KEYNOTE-522 pembrolizumab and OlympiA olaparib now compete in this setting.

Used in

Triple-negative breast cancer (TNBC)HR-positive / HER2-negative breast cancer

Source

CREATE-X, NEJM 2017

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Advanced progressive NET (RADIANT-3, RADIANT-4); RCC and HR-positive breast cancer after prior therapy

Dose-dense AC → T

Node-positive or high-risk early breast cancer, adjuvant or neoadjuvant

every 14 days × 4

TC (docetaxel + cyclophosphamide)

Early breast cancer when an anthracycline is not wanted

every 21 days × 4

KEYNOTE-522 (pembrolizumab + chemotherapy, then adjuvant pembrolizumab)

Stage II-III triple-negative breast cancer

every 21 days × 4

Trastuzumab deruxtecan 5.4 mg/kg

HER2-positive metastatic breast cancer second line; HER2-low or ultralow after chemotherapy or endocrine therapy; HER2-mutant NSCLC

Sacituzumab govitecan

Metastatic TNBC after two lines (one for metastatic disease); HR-positive after endocrine therapy and two chemotherapies

Olaparib (adjuvant, OlympiA)

Germline BRCA1/2, HER2-negative, high-risk early breast cancer after chemotherapy

every 28 days × 13

CDK4/6 inhibitor + aromatase inhibitor

HR-positive, HER2-negative advanced breast cancer, first line (and adjuvant abemaciclib or ribociclib for high-risk early disease)

All regimens Olaparib (adjuvant, OlympiA) →